President Donald Trump announced on Sunday that he intends to sign an executive order aimed at significantly lowering prescription drug prices, potentially by “30% to 80%” almost immediately.
These actions represent what he terms the new “most advantageous national policies,” which would require the U.S. to align its drug prices with those in countries where they are lowest globally.
It’s something that’s been on Trump’s agenda for a long time, utilizing price indicators from nations like Canada, the UK, and Japan. The proposal aims for Medicare to establish drug prices based on what doctors actually pay in the domestic market. However, this initiative and related legislative efforts have faced strong opposition from the pharmaceutical industry and some bipartisan members within Congress.
After Trump signed an executive order in 2020 to tackle drug prices, he is now revisiting this commitment, indicating a need to reduce costs without burdening American citizens due to shortages created by nationalized healthcare systems abroad.
Following this, the Centers for Medicare and Medicaid Services released interim rules to implement the presidential directives, which led to legal challenges from various pharmaceutical industry trade associations aiming to block these rules.
The subsequent Biden administration moved quickly to cancel the previously ordered pricing reforms after a court ruled against them.
Trump is apparently feeling optimistic about this new attempt, even as many of the adversaries of his price reduction initiatives are still in office.
He remarked, “We’re going to do the right thing, something that Democrats have fought for for years.”
In his communications, he shared a reflection, “For years, I’ve been puzzled why prescription medications cost so much more in the U.S.—often 5 to 10 times higher than elsewhere for the same products. It’s a tough conversation to have with people, especially without clear answers.”
According to a recent analysis conducted by RAND Health Care for the Department of Health and Human Services, U.S. drug prices, both for brand names and generics, were almost 2.78 times higher than those in comparable countries. After adjusting for rebates specific to the U.S., brand drug prices still proved to be at least 3.22 times more expensive than in other nations.
Trump countered the pharmaceutical industry’s usual claims about funding research and development, pointing out that American taxpayers often bear the brunt of these costs. He noted, “While they claim these high prices are necessary for innovation, I don’t support that narrative. We’re going to prioritize what’s right. Democrats have been fighting this issue for too long.”
He added that while costs may decrease for American consumers, the global drug prices will have to align as well, ensuring parity for the first time in years.
Pharmaceutical lobbyists have begun to express their discontent with the anticipated executive order, suggesting it would be “one of the most impactful announcements on this subject in years.”
In their statement, they argued, “This pricing model is detrimental for American patients. Importing prices from other countries could slash billions from Medicare, but we can’t be sure it will actually help patients access the medications they need.”
Additionally, they voiced concerns about how such moves could stifle investment in the U.S. economy, hinting at reliance on foreign resources for medical advancements.
Trump has already made strides this year concerning drug pricing, guiding his administration to enhance transparency standards and bolster “universal access to understandable and accurate health pricing information.”
